Update date
31 Oct 2025
Shareable Research Card
CMND - Clearmind Medicine Inc. Research And Development Expense
This metric view shows CMND - Clearmind Medicine Inc. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q3 2025
- Latest reported value
- $420,182
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Oct 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q3 2025.
- Latest reported value on this page: $420,182.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: $420,182. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q3 2025
SEC-backed company facts were refreshed from filings filed on 20 Jan 2026.
Benchmark Context
How Research And Development Expense compares with peers
Clearmind Medicine Inc. is outside the visible top 120 companies for research and development expense in the current sample.
Compared with
Compared with 120 companies reporting research and development expense in USD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Research And Development Expense is down about 14% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2017 to 31 Dec 2025.
- Nearby companies in this sample: ASTRAZENECA PLC and NOVARTIS AG.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
Clearmind Medicine Inc.: Research And Development Expense
Latest period: Q3 2025. Period end: 31 Oct 2025. Units: USD and CAD. Frequency: quarterly and annual.
Research And Development Expense is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- $420,182
- Coverage range
- 31 Oct 2021 - 31 Oct 2025
- Fact rows
- 22
What this metric tells you
- Shows reported research and development expense over 31 Oct 2021 - 31 Oct 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 22 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
- Use the TTM line to smooth quarter-to-quarter noise.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View financial facts overview
- Clearmind Medicine Inc. SEC filings
- Latest 10-Q/10-K hub
- Open SEC company facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | ASTRAZENECA PLC (azn) | $14,232,000,000 | Year - 31 Dec 2025 | Open ASTRAZENECA PLC Research And Development Expense |
| 2 | NOVARTIS AG (nvs) | $11,200,000,000 | Year - 31 Dec 2025 | Open NOVARTIS AG Research And Development Expense |
| 3 | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (tsm) | $6,227,000,000 | Year - 31 Dec 2024 | Open TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD Research And Development Expense |
| 4 | GENMAB A/S (gmab) | $1,606,000,000 | Year - 31 Dec 2025 | Open GENMAB A/S Research And Development Expense |
| 5 | Atlassian Corp (team) | $1,397,568,000 | Year - 30 Jun 2022 | Open Atlassian Corp Research And Development Expense |
| 6 | ARGENX SE (argx) | $1,364,132,000 | Year - 31 Dec 2025 | Open ARGENX SE Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Frequency coverage
-
quarterly and annual
Comparability: Compare annual with annual and quarterly with quarterly
- Taxonomy
- ifrs-full
- Units tracked
- USD and CAD
- History range
-
31 Oct 2021 - 31 Oct 2025
Freshness: From parsed SEC XBRL facts on this page
- Facts on this page
-
22
Source: SEC company facts API
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Trailing 12 Months (USD)
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (USD)
Research And Development Expense, YoY Annual Change (%)
Research And Development Expense, Quarterly (CAD)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (CAD)
Research And Development Expense, YoY Annual Change (%)
Clearmind Medicine Inc. Quarterly Research And Development Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2025 | $2,056,525 | $420,182 | -$66,309 | -14% | 01 Aug 2025 | 31 Oct 2025 | 20-F | 20 Jan 2026 | 2025 | FY |
| Q2 2025 | $2,122,834 | $723,048 | +$377,165 | +109% | 01 May 2025 | 31 Jul 2025 | 6-K | 11 Sep 2025 | 2025 | Q3 |
| Q1 2025 | $1,745,669 | $451,857 | +$128,901 | +40% | 01 Feb 2025 | 30 Apr 2025 | 6-K | 12 Jun 2025 | 2025 | Q2 |
| Q4 2024 | $1,616,768 | $461,438 | +$233,960 | +103% | 01 Nov 2024 | 31 Jan 2025 | 6-K | 13 Mar 2025 | 2025 | Q1 |
| Q3 2024 | $1,382,808 | $486,491 | +$111,418 | +30% | 01 Aug 2024 | 31 Oct 2024 | 20-F | 20 Jan 2026 | 2025 | FY |
| Q2 2024 | $1,271,390 | $345,883 | +$81,929 | +31% | 01 May 2024 | 31 Jul 2024 | 6-K | 11 Sep 2025 | 2025 | Q3 |
| Q1 2024 | $1,189,461 | $322,956 | +$5,384 | +1.7% | 01 Feb 2024 | 30 Apr 2024 | 6-K | 12 Jun 2025 | 2025 | Q2 |
| Q4 2023 | $1,184,077 | $227,478 | -$360,152 | -61% | 01 Nov 2023 | 31 Jan 2024 | 6-K | 13 Mar 2025 | 2025 | Q1 |
| Q3 2023 | $1,544,229 | $375,073 | 01 Aug 2023 | 31 Oct 2023 | 20-F | 20 Jan 2026 | 2025 | FY | ||
| Q2 2023 | $263,954 | 01 May 2023 | 31 Jul 2023 | 6-K | 16 Sep 2024 | |||||
| Q1 2023 | $317,572 | -$843,186 | -73% | 01 Feb 2023 | 30 Apr 2023 | 6-K | 13 Jun 2024 | |||
| Q4 2022 | $587,630 | 01 Nov 2022 | 31 Jan 2023 | 6-K | 19 Mar 2024 | |||||
| Q1 2022 | $1,160,758 | 01 Feb 2022 | 30 Apr 2022 | 6-K | 14 Jun 2023 |
Clearmind Medicine Inc. Annual Research And Development Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $2,056,525 | +$673,717 | +49% | 01 Nov 2024 | 31 Oct 2025 | 20-F | 20 Jan 2026 | 2025 | FY |
| 2024 | $1,382,808 | -$161,421 | -10% | 01 Nov 2023 | 31 Oct 2024 | 20-F | 20 Jan 2026 | 2025 | FY |
| 2023 | $1,544,229 | -$1,536,762 | -50% | 01 Nov 2022 | 31 Oct 2023 | 20-F | 20 Jan 2026 | 2025 | FY |
| 2022 | $3,080,991 | +$2,607,339 | +550% | 01 Nov 2021 | 31 Oct 2022 | 20-F | 22 Jan 2025 | 2024 | FY |
| 2021 | $473,652 | 01 Nov 2020 | 31 Oct 2021 | 20-F/A | 18 Mar 2024 | 2023 | FY |
Clearmind Medicine Inc. Quarterly Research And Development Expense (CAD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2022 | CA$792,460 | +CA$368,198 | +87% | 01 Nov 2022 | 31 Jan 2023 | 6-K | 17 Mar 2023 | |||
| Q4 2021 | CA$424,262 | 01 Nov 2021 | 31 Jan 2022 | 6-K | 17 Mar 2023 |
Clearmind Medicine Inc. Annual Research And Development Expense (CAD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | CA$4,205,245 | +CA$3,558,758 | +550% | 01 Nov 2021 | 31 Oct 2022 | 20-F | 06 Feb 2023 | 2022 | FY |
| 2021 | CA$646,487 | 01 Nov 2020 | 31 Oct 2021 | 20-F | 06 Feb 2023 | 2022 | FY |
* marks a reported value that did not pass the local value check.